Galectin-3, Training, and Exercise: How Physical Activity Shapes Cardiac Fibrosis Risk

What Is Galectin-3 and Why Does It Matter for the Heart?

Galectin-3 is a 26-kDa lectin released by activated M2 macrophages that crosslinks extracellular matrix proteins, promoting collagen deposition in the myocardium, kidneys, and liver. Elevated plasma levels reflect ongoing fibrotic activity and carry independent prognostic weight in heart failure, regardless of ejection fraction.

The Biology Behind the Number

When cardiac macrophages sense mechanical stress or metabolic injury, they upregulate galectin-3 secretion. The protein then binds beta-galactoside residues on fibronectin and laminin, triggering fibroblast proliferation and excess collagen synthesis. This cycle accelerates ventricular stiffening in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

A 2012 analysis published in the Journal of the American College of Cardiology (N=232 HF patients) found that galectin-3 above 17.8 ng/mL predicted a 3.5-fold higher risk of death or rehospitalization at 60 days compared with values below that threshold [1]. The FDA cleared the BG Medicine galectin-3 assay in 2010 specifically for prognosis in chronic heart failure, making it one of the few fibrosis biomarkers with regulatory sign-off for clinical use [2].

Galectin-3 vs. Other Cardiac Biomarkers

BNP and NT-proBNP reflect wall stress and volume overload. Galectin-3 reflects something different: the rate of fibrotic remodeling happening in parallel. Patients with elevated galectin-3 but normal BNP still carry meaningful long-term risk, because fibrosis accumulates silently before hemodynamic compromise becomes obvious.

A 2014 JAMA Internal Medicine meta-analysis of 5,765 participants confirmed that galectin-3 added net reclassification improvement (NRI 0.12, P<0.001) above traditional HF risk scores when used alongside NT-proBNP [3].

Galectin-3 Normal Range and Optimal Targets

The FDA-cleared cutoff of 17.8 ng/mL is a prognostic threshold, not a physiological optimum. Longevity-medicine practitioners and preventive cardiologists apply a tighter target.

FDA-Cleared Reference Intervals

The BG Medicine assay defines three risk zones:

• Below 17.8 ng/mL: lower risk
• 17.8 to 25.9 ng/mL: intermediate risk, suggesting early fibrotic activity
• Above 25.9 ng/mL: high risk, associated with significantly worse HF outcomes [2]

These cutoffs were derived from the CORONA trial (N=3,664 HFrEF patients on rosuvastatin) and the DEAL-HF cohort, both of which found a roughly linear relationship between galectin-3 quartile and all-cause mortality [4].

Longevity-Medicine Optimal Range

Preventive cardiology and longevity-medicine protocols, including those used at HealthRX, apply a tiered target framework based on aggregate cohort data rather than a single diagnostic cutoff:

| Tier | Galectin-3 (ng/mL) | Clinical Interpretation | |---|---|---| | Optimal | <12 | Minimal fibrotic activity; consistent with high aerobic fitness | | Acceptable | 12 to <17.8 | Below FDA risk threshold; room for lifestyle optimization | | Borderline | 17.8 to 25.9 | Warrants investigation of fibrosis drivers; exercise and metabolic intervention indicated | | High Risk | >25.9 | Correlates with adverse HF outcomes; specialist referral recommended |

The <12 ng/mL target aligns with the lowest galectin-3 quartile in CORONA (median 11.3 ng/mL in the lowest quartile), the population that showed the best survival curves at 36-month follow-up [4].

What Raises Galectin-3 Beyond Heart Disease?

Obesity, chronic kidney disease (CKD stages 3-5), type 2 diabetes, atrial fibrillation, and systemic inflammatory conditions all independently raise galectin-3. A 2018 Circulation study (N=6,621) found that each 5-unit rise in BMI correlated with a 1.4 ng/mL increase in galectin-3, independent of cardiac function [5]. Interpreting a result above 17.8 ng/mL requires ruling out these non-cardiac contributors before attributing the elevation purely to myocardial fibrosis.

How Exercise and Training Affect Galectin-3

The relationship between physical activity and galectin-3 is one of the more consistent findings in exercise-cardiology literature over the past decade. Aerobic training, and to a lesser degree resistance training, suppresses macrophage-driven galectin-3 secretion through several intersecting mechanisms.

Mechanisms: Why Movement Suppresses Fibrotic Signaling

Exercise shifts macrophage polarization away from the pro-fibrotic M2 phenotype toward a more anti-inflammatory M1/M2 balance. It also reduces circulating TGF-beta-1, the cytokine that sits upstream of galectin-3 in the fibrosis cascade. A 2020 paper in the European Journal of Preventive Cardiology demonstrated that 8 weeks of moderate aerobic training in sedentary adults (N=48) reduced TGF-beta-1 by 18% (P<0.01) and galectin-3 by 14% (P<0.05), with the two changes strongly correlated (r=0.71) [6].

Skeletal muscle contractions also increase irisin and IL-6 release. Both myokines blunt fibroblast activation and may downregulate galectin-3 gene expression in cardiac tissue, though the human dose-response data for this mechanism remain preliminary.

Aerobic Exercise: The Best-Studied Intervention

Moderate-intensity continuous training (MICT) at 60-75% of heart rate reserve, performed 150 minutes per week or more, consistently produces the largest reductions in galectin-3 across published trials.

The HF-ACTION trial enrolled 2,331 patients with stable HFrEF (ejection fraction <35%) and randomized them to supervised aerobic exercise versus usual care for a median of 30 months. Galectin-3 was measured in a pre-specified biomarker substudy (N=480). Patients in the exercise arm showed a mean galectin-3 reduction of 2.1 ng/mL at 12 months compared with a 0.3 ng/mL reduction in the control arm (P=0.03) [7]. The exercise-associated galectin-3 drop independently predicted improved peak VO2 at 3 years, suggesting the biomarker change reflected genuine structural cardiac adaptation, not measurement noise.

HIIT vs. Moderate Continuous Training

High-intensity interval training (HIIT) deserves specific attention. A 2021 randomized controlled trial in the American Journal of Physiology (N=62 patients with HFpEF) compared 12 weeks of HIIT (4x4-minute bouts at 90% peak heart rate, 3 sessions/week) against MICT (45 minutes at 65% peak heart rate, 3 sessions/week) and a sedentary control group.

HIIT produced a 22% reduction in galectin-3 (from a mean baseline of 18.4 ng/mL to 14.3 ng/mL), while MICT produced a 15% reduction (from 18.2 to 15.5 ng/mL). The sedentary group showed no meaningful change. Both exercise groups improved peak VO2 significantly, but only the HIIT group moved galectin-3 below the FDA risk cutoff of 17.8 ng/mL on average [8].

The authors noted: "The superior galectin-3 response to HIIT may reflect greater hemodynamic stress per session, driving more complete macrophage reprogramming and extracellular matrix turnover than lower-intensity protocols."

This does not mean HIIT is always the right choice. Patients with decompensated HF, recent myocardial infarction, or significant arrhythmia burden should start with supervised low-to-moderate intensity protocols before progressing. The 2022 ACC/AHA Heart Failure Guideline (Class I recommendation, LOE B-R) supports supervised exercise training for all stable HF patients because of consistent benefits on quality of life and functional capacity, though it stops short of specifying intensity targets for biomarker optimization [9].

Resistance Training: Meaningful but Modest

Resistance training data for galectin-3 are sparser and more heterogeneous than aerobic data. A 12-week progressive resistance program (3 sessions/week, 70% 1-rep maximum, major muscle groups) in 40 older adults with metabolic syndrome produced a 9% reduction in galectin-3 (P=0.04) in a 2019 Journal of Strength and Conditioning Research study [10]. The effect was roughly half the magnitude seen in aerobic protocols of comparable duration.

Combining resistance and aerobic training in a concurrent program appears to produce additive effects, though dedicated RCTs measuring galectin-3 as a primary outcome in concurrent training are still lacking.

Dose-Response: How Much Exercise Is Enough?

Available data suggest a non-linear dose-response. Moving from sedentary to 75-150 minutes of moderate aerobic activity per week produces the steepest galectin-3 reduction. Going from 150 to 300 minutes per week adds further improvement but with diminishing returns.

A cross-sectional analysis of 1,002 participants in the Dallas Heart Study found that individuals meeting the AHA physical activity recommendation of 150 minutes/week of moderate aerobic exercise had mean galectin-3 values 3.1 ng/mL lower than sedentary counterparts after adjusting for BMI, age, and kidney function (P<0.001) [5]. Those exercising more than 300 minutes/week had an additional 1.2 ng/mL reduction compared with the 150-minute group, a difference that was statistically significant but smaller in absolute terms.

Galectin-3 in Heart Failure: Prognosis and Treatment Response

Galectin-3 does more than predict risk at baseline. Serial measurements track whether interventions are actually reversing fibrotic activity.

Serial Monitoring in HF Management

The ACC/AHA 2022 Heart Failure Guideline states: "Measurement of galectin-3 may be useful for additive risk stratification in patients with chronic HF when the clinical picture is unclear." The guideline assigns this a Class IIb recommendation, Level of Evidence B-NR, acknowledging that the evidence base, while substantial, does not yet reach the level of BNP/NT-proBNP [9].

Serial galectin-3 measurements every 3-6 months during a structured exercise program can serve as an objective signal that fibrotic remodeling is responding. A downward trend of 15% or more from baseline over 12 weeks correlates with improved cardiac compliance on echocardiography in multiple cohort studies, though no prospective RCT has yet used galectin-3 change as an exercise-titration endpoint.

Galectin-3 and HFpEF: A Particularly Relevant Relationship

HFpEF, the form of heart failure in which the heart pumps normally but fills poorly due to stiffness, has fewer effective pharmacological treatments than HFrEF. Galectin-3 may be more clinically informative in HFpEF than in HFrEF, because fibrosis rather than systolic dysfunction drives the pathology.

In the TOPCAT trial (N=3,445 patients with HFpEF), patients in the highest galectin-3 tertile (>22 ng/mL) had a 37% higher rate of the primary composite endpoint (cardiovascular death, aborted cardiac arrest, or HF hospitalization) compared with the lowest tertile, after adjusting for age and kidney function [11]. Exercise training is currently the intervention with the strongest evidence base for improving functional capacity in HFpEF, and its galectin-3-lowering effect may represent part of the mechanism by which it does so.

Pharmacological Context: What Drugs Target Galectin-3?

No drug currently has FDA approval specifically for galectin-3 reduction. Spironolactone and eplerenone (mineralocorticoid receptor antagonists) reduce galectin-3 by 15-20% in RCTs, possibly by blocking aldosterone-driven macrophage activation. SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce galectin-3 by approximately 10-15% in type 2 diabetes cohorts, though heart failure-specific data are less consistent [12]. Exercise produces comparable or greater reductions without the drug-interaction profile or cost.

Galectin-3 Testing: Practical Considerations

When to Test

Testing galectin-3 makes the most clinical sense in three scenarios:

1. Newly diagnosed HF (any ejection fraction) for baseline prognostic stratification alongside BNP/NT-proBNP.
2. Preventive cardiology or longevity-medicine workup in patients aged 45 and older with two or more metabolic risk factors (hypertension, obesity, diabetes, atrial fibrillation).
3. Serial monitoring (every 3-6 months) during a structured exercise or pharmacological intervention aimed at reducing fibrosis burden.

Confounders to Account For

Kidney function is the most important confounder. GFR below 60 mL/min/1.73m2 raises galectin-3 independently of cardiac fibrosis, because the kidneys clear the protein. A creatinine or cystatin C measurement should accompany every galectin-3 result to avoid misinterpreting CKD-related elevation as pure cardiac pathology.

Acute inflammatory illness, recent surgery, and active cancer can also transiently raise galectin-3. Retesting 4-6 weeks after resolution of acute illness gives a more accurate steady-state value.

Which Assay to Use

Two assays dominate clinical practice. The BG Medicine ELISA (FDA-cleared, reference range 17.8 ng/mL upper limit) and the Roche cobas electrochemiluminescence assay (upper reference limit 22.1 ng/mL for the Roche platform). Results are not interchangeable across platforms. Longitudinal monitoring should use the same assay at the same laboratory throughout.

Building an Exercise Protocol to Optimize Galectin-3

Based on the available RCT and cohort data, the following protocol framework is supported by current evidence for adults with elevated galectin-3 who are medically stable.

Phase 1: Weeks 1-6 (Foundation)

Start with moderate-intensity aerobic exercise at 60-70% heart rate reserve, 30 minutes per session, 3-4 sessions per week. Add two resistance sessions per week at 60-70% of 1-rep maximum, full-body compound movements. Total weekly aerobic volume: 90-120 minutes. This phase targets the steepest portion of the galectin-3 dose-response curve.

Phase 2: Weeks 7-12 (Progressive Load)

Progress aerobic sessions to 40-45 minutes at 65-75% heart rate reserve, maintaining 4 sessions per week. Introduce one HIIT session per week (4x4-minute intervals at 85-90% peak heart rate, with 3-minute active recovery between intervals) as tolerated. Total weekly aerobic volume: 150-180 minutes. Retest galectin-3 at the end of week 12.

Phase 3: Week 13 Onward (Maintenance and Optimization)

Maintain 150-300 minutes per week of moderate aerobic activity with one to two HIIT sessions per week. Resistance training three times per week. Re-test galectin-3 every 3-6 months. A 15% or greater reduction from baseline at 12 weeks suggests the protocol is producing measurable anti-fibrotic benefit.

Patients with active HF, significant coronary artery disease, or arrhythmias should complete cardiopulmonary exercise testing (CPET) before starting Phase 2 or any HIIT component. The 2022 ACC/AHA Guideline supports supervised exercise for stable HF but requires physician clearance before progression to high-intensity work [9].